◆英語タイトル:Indivior Plc (INDV) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C0274
◆発行会社(調査会社):
GlobalData
◆発行日:2018年7月
◆ページ数:67
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Indivior Plc (INDV) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Indivior Plc (Indivior) develops and commercializes medicines for the treatment of opioid addiction. The company offers suboxone a monthly depot, and only approved film treatment for opioid dependence in the US. Its pipeline portfolio encompasses buprenorphine-based products, including C4X-3256 in pre-clinical phase for opioid dependence treatment; ADX-71441 in pre-clinical phase for cocaine use disorder; Arbaclofen Placarbil in Phase 1 for alcohol use disorder; and RBP-7000 for schizophrenia. Indivior offers products in the form of film, tablets, and subutex tabs. It offers its products in the US, Australia, Malaysia, France, Italy, Spain, Germany, Canada and the UK. Indivior is headquartered in Slough, the UK.
Indivior Plc Key Recent Developments
Jul 11,2018: Indivior Sees FY 2018 Net Revenue and Adjusted Net Income Below Previous Expectations
Jun 28,2018: Indivior’s Temporary Restraining Order is Extended
May 02,2018: Indivior: Q1 2018 Results
Mar 29,2018: Indivior Enters Into An Exclusive Global License Agreement For C4X Discovery’s Orexin-1 (OX1) Antagonist Program
Feb 15,2018: Indivior Reports Full Year 2017 Financial Results
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Indivior Plc – Key Facts 6
Indivior Plc – Key Employees 7
Indivior Plc – Key Employee Biographies 8
Indivior Plc – Major Products and Services 10
Indivior Plc – History 11
Indivior Plc – Company Statement 12
Indivior Plc – Locations And Subsidiaries 14
Head Office 14
Other Locations & Subsidiaries 14
Section 2 – Company Analysis 17
Company Overview 17
Indivior Plc – Business Description 18
R&D Overview 18
Indivior Plc – SWOT Analysis 19
SWOT Analysis – Overview 19
Indivior Plc – Strengths 19
Indivior Plc – Weaknesses 20
Indivior Plc – Opportunities 21
Indivior Plc – Threats 22
Indivior Plc – Key Competitors 23
Section 3 – Company Financial Ratios 24
Financial Ratios – Capital Market Ratios 24
Financial Ratios – Annual Ratios 25
Performance Chart 28
Financial Performance 28
Financial Ratios – Interim Ratios 29
Financial Ratios – Ratio Charts 30
Section 4 – Company’s Lifesciences Financial Deals and Alliances 31
Indivior Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31
Indivior Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 32
Indivior Plc, Recent Deals Summary 33
Section 5 – Company’s Recent Developments 34
Jul 11, 2018: Indivior Sees FY 2018 Net Revenue and Adjusted Net Income Below Previous Expectations 34
Jun 28, 2018: Indivior’s Temporary Restraining Order is Extended 35
May 02, 2018: Indivior: Q1 2018 Results 36
Nov 02, 2017: Indivior: Nine Month Financial Results – FY 2017 41
Nov 02, 2017: Indivior- Board Committee Changes 49
Aug 22, 2017: Indivior Opens $30 Million Research and Development Center to Advance Treatment Innovation 50
Jul 27, 2017: Indivior H1 2017 Financial Results 51
Feb 22, 2017: Indivior: FY 2016 Financial Results 56
Feb 03, 2017: Indivior: Director Declaration 61
Jan 24, 2017: Indivior: Appointment of Non-Executive Director 62
Section 6 – Appendix 63
Methodology 63
Ratio Definitions 63
About GlobalData 67
Contact Us 67
Disclaimer 67
List of Tables
Indivior Plc, Key Facts 6
Indivior Plc, Key Employees 7
Indivior Plc, Key Employee Biographies 8
Indivior Plc, Major Products and Services 10
Indivior Plc, History 11
Indivior Plc, Subsidiaries 14
Indivior Plc, Key Competitors 23
Indivior Plc, Ratios based on current share price 24
Indivior Plc, Annual Ratios 25
Indivior Plc, Annual Ratios (Cont...1) 26
Indivior Plc, Annual Ratios (Cont...2) 27
Indivior Plc, Interim Ratios 29
Indivior Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31
Indivior Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 32
Indivior Plc, Recent Deals Summary 33
Currency Codes 63
Capital Market Ratios 63
Equity Ratios 64
Profitability Ratios 64
Cost Ratios 65
Liquidity Ratios 65
Leverage Ratios 66
Efficiency Ratios 66
List of Figures
Indivior Plc, Performance Chart (2013 - 2017) 28
Indivior Plc, Ratio Charts 30
Indivior Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31
Indivior Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 32